Cellectar Biosciences Inc (CLRB)

[Crusader]

Thanks for the early news post, AO!

This paragraph was of the most interest to me:

"...While it is also premature to report survival-related efficacy data from Cohort 3, all patients in Cohorts 1 and 2 continue to experience overall survival benefit. Patients from Cohort 1, who received a single 12.5 mCi/m2 dose, have experienced, to date, mOS of 17.7 months. Cohort 2 patients, who received a single 18.75 mCi/m2 dose, have a current median overall survival of 8.4 months. Based on this data, the company has the option of using an 18.75 mCi/m2 single or multi-dose regimen as monotherapy or in combination with other agents as a therapeutic dose in future clinical studies evaluating efficacy. Importantly, median overall survival for all evaluable patients in each cohort continues to increase, and the company will continue to follow these patients to determine the full extent of the overall survival benefit of CLR 131. ." .

A FEW MORE FAVORABLE PRESS RELEASES LIKE THIS ONE WITH SPECIFFIC THERAPUTICAL FACTS INCLUDED, AND THE MARKET WILL WAKE UP TO THIS BIOTECH!